Diamonds and Dogs
7/26/13Expedia Inc. (EXPE)
Expedia is a bad trip for investors today, down 27.39% at $47.20. The online travel company saw its shares fall after a big miss on earnings for the second quarter. Expedia management announced an EPS of $0.64 on revenue of $1.21 billion. Wall Street analysts were expecting the company to earn $0.79 per share on revenue of $1.26 billion. The big missed caused analysts to cut their price targets for the company. Jefferies analyst, Brian Fitzgerald cut his target from $68 to $59. Expedia shares fell to a new 52-week low of $47.55 intraday.
Gentium S.p.A (GENT)
Gentium is trading in the green today, up 51.78% at $15.81. The biopharmaceutical company saw its shares skyrocket after news that it received positive opinion from the European Medicine's Agency (EMA). The positive opinion for Gentium's product, Defitelio, allows for a Marketing Authorization Application ("MAA") under exceptional circumstances, for the treatment of severe hepatic veno-occlusive disease ("VOD") in adults and children undergoing hematopoietic stem cell transplantation therapy. The positive opinion is a good sign for Gentium, however the European Commission will review the EMA's decision and has final authority. Gentium shares hit a new 52-week high of $15.90 intraday.